Platelet-rich plasma in equine joints still lacks a clear playbook
Bottom line
Platelet-rich plasma remains popular in equine joint care, but the evidence base still hasn’t caught up with how widely the therapy is used. Recent reviews of the literature say PRP is being applied for equine osteoarthritis and other joint problems despite major variation in how products are prepared, whether they contain leukocytes, how they’re activated, and how they’re delivered into joints. That heterogeneity makes studies hard to compare and leaves clinicians without a clear consensus on the best protocol. At the same time, interest in orthobiologics continues to grow across equine practice, especially as same-day, stall-side options appeal to sports medicine clinicians. (mdpi.com)
Why it matters: For veterinary professionals, the practical takeaway is that PRP may still have a place in selected cases, but product characterization matters. Reviews and expert guidance suggest equine PRP studies are limited, often inconsistent, and frequently underreport key variables such as platelet concentration, white blood cell content, red blood cell contamination, and activation method. AAEP proceedings note that this variability makes meaningful comparison nearly impossible, while some experts say PRP is used more often for soft-tissue injury than as an intra-articular therapy in horses. In other words, “PRP” isn’t one uniform treatment, which complicates case selection, client communication, and outcome expectations. (aaep.org)
What to watch: Expect more focus on standardized reporting, better product validation, and head-to-head studies that clarify which PRP formulations, if any, work best for specific equine joint conditions. (mdpi.com)
Key facts
- Topic
- Platelet-rich plasma (PRP) is widely used in equine joint therapy
- Use cases
- Equine osteoarthritis and other joint disease
- Main issue
- Studies use different collection systems, platelet concentrations, leukocyte profiles, activation methods, and dosing approaches
- Reporting gap
- Many papers do not fully describe the final biologic being injected
- Evidence quality
- Recent reviews describe the evidence as limited, inconsistent, and conflicting
- Clinical role
- Support for intra-articular PRP use in horses remains limited
- Practice pattern
- PRP is used primarily for soft-tissue injury and only rarely as an intra-articular therapy in horses
- Regulatory note
- FDA said in 2024 that PrecisePRP Equine became the first reviewed concentrated platelet-in-plasma product for intra-articular injection in horses
Platelet-rich plasma is still firmly in the conversation for equine joint therapy, but the field is in a familiar place: strong clinical interest, uneven evidence, and no real agreement on the best way to prepare or use it. Recent systematic reviews and expert summaries describe PRP as widely used for equine osteoarthritis and joint disease, yet still difficult to evaluate because studies use different collection systems, platelet concentrations, leukocyte profiles, activation methods, and dosing approaches. (mdpi.com)
That tension has been building for years. Earlier reviews had already flagged the lack of consensus around PRP processing and the challenge of comparing patented kits with manual methods. More recent literature suggests the problem hasn’t been solved. A 2025 scoping review focused specifically on heterogeneity in equine PRP therapies found persistent variation in preparation methods and called for minimum reporting guidelines to improve reproducibility and clinical translation. (link.springer.com)
The newer evidence is useful, but still not definitive. A 2024 systematic review in Animals concluded that PRP may help reduce joint inflammation and support tissue repair in horses with osteoarthritis, but emphasized that the available studies are limited and inconsistent. A separate systematic review and meta-analysis published in 2024 similarly found conflicting evidence for PRP products in equine joint disease. Across the literature, a recurring issue is that many papers do not fully describe the final biologic being injected, making it hard to know whether positive or negative outcomes reflect PRP itself or the way that particular product was made. (mdpi.com)
Expert commentary from the field reinforces that point. In the 2025 AAEP Resort Symposium proceedings, PRP is described as difficult to classify because of differences in platelet concentration, white blood cell and red blood cell content, centrifugation steps, and activation methods. The same proceedings note that, despite extensive human knee osteoarthritis literature, support for intra-articular PRP use in horses remains limited and more research is needed to define its role in joint disease. The author also notes that in clinical practice, PRP is used primarily for soft tissues and only rarely as an intra-articular therapy. (aaep.org)
There are also signs the science is evolving beyond traditional autologous PRP. EquiManagement previously reported on work presented by Lauren Schnabel, DVM, PhD, DACVS, DACVSMR, describing a concentrated PRP lysate approach for osteoarthritis and joint infection applications. That work highlighted interest in platelet-derived products not just for growth factor delivery, but also for antimicrobial, anti-biofilm, and chondroprotective effects. Separately, FDA said in 2024 that PrecisePRP Equine, a concentrated platelet-in-plasma product for intra-articular injection, became the first such reviewed product for use in horses, a sign that the regulatory landscape around equine orthobiologics is also becoming more structured. (equimanagement.com)
Why it matters: For equine veterinarians, the current state of play argues for caution, specificity, and transparency. PRP may be attractive because it’s relatively accessible, often processed the same day, and aligns with demand for biologic options in performance horses. But the literature suggests clinicians shouldn’t treat all PRP products as interchangeable. Case selection, joint pathology, chronicity, competition schedules, and the exact formulation being used likely matter. That means conversations with pet parents and trainers should center on uncertainty as much as promise, especially when discussing expected duration of benefit, repeat injections, and how PRP compares with corticosteroids, ACS/IRAP, APS, or other orthobiologics. (aaep.org)
The bigger issue is evidence quality. If future studies consistently report baseline blood counts, final platelet yield, leukocyte content, activation method, dose, and injection schedule, the field may finally be able to identify which formulations work best for which indications. Until then, PRP remains a therapy with real biologic rationale and real clinical uptake, but incomplete standardization and incomplete answers. (mdpi.com)
What to watch: Watch for standardized reporting frameworks, validated commercial systems, and prospective equine trials that compare specific PRP formulations against established joint therapies on clear timelines and outcome measures. (mdpi.com)